相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。An Insight into Cholangiocarcinoma and Recent Advances in its Treatment
Rakesh Sahu et al.
JOURNAL OF GASTROINTESTINAL CANCER (2023)
Controversial risk factors for cholangiocarcinoma
Firas Baidoun et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2022)
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry
Laura Izquierdo-Sanchez et al.
JOURNAL OF HEPATOLOGY (2022)
Cholangiocarcinoma protective factors in Greater Mekong Subregion: Critical issues for joint planning to sustainably solve regional public health problems
Nopparat Songserm et al.
PLOS ONE (2022)
Factors associated with failure to rescue after major hepatectomy for perihilar cholangiocarcinoma: A 15-year single-center experience
Christian Benzing et al.
SURGERY (2022)
Utility of Cell-Free DNA Detection in Transplant Oncology
Tejaswini Reddy et al.
CANCERS (2022)
Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis
Jessica J. Holster et al.
ANNALS OF SURGICAL ONCOLOGY (2022)
Predictive factors for subsequent intrahepatic cholangiocarcinoma associated with hepatolithiasis: Japanese National Cohort Study for 18 years
Yutaka Suzuki et al.
JOURNAL OF GASTROENTEROLOGY (2022)
Effectiveness of Village Health Volunteer Parallel Program for Proactive Action to Reduce Risk Factors for Cholangiocarcinoma in Two High-Risk Countries in the Greater Mekong Subregion
Nopparat Songserm et al.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL (2022)
Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View
Maen Abdelrahim et al.
CANCERS (2022)
Gemcitabine and Cisplatin as Neo-Adjuvant for Cholangiocarcinoma Patients Prior to Liver Transplantation: Case-Series
Maen Abdelrahim et al.
CURRENT ONCOLOGY (2022)
Antibody-drug conjugates in HER2-positive breast cancer
Lixi Li et al.
CHINESE MEDICAL JOURNAL (2022)
Stereotactic radiotherapy in intrahepatic cholangiocarcinoma: A systematic review
Silvia Bisello et al.
Molecular and Clinical Oncology (2021)
Survival benefit with adjuvant radiotherapy after resection of distal cholangiocarcinoma: A propensity-matched National Cancer Database analysis
Sivesh K. Kamarajah et al.
CANCER (2021)
Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study.
Funda Meric-Bernstam et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Surgical Therapy for Perihilar Cholangiocarcinoma: State of the Art
Lynn E. Nooijen et al.
VISCERAL MEDICINE (2021)
Targeting FGFR inhibition in cholangiocarcinoma
Lipika Goyal et al.
CANCER TREATMENT REVIEWS (2021)
Triple-Regimen of Vemurafenib, Irinotecan, and Cetuximab for the Treatment of BRAFV600E-Mutant CRC: A Case Report and Review
Su Min Cho et al.
FRONTIERS IN PHARMACOLOGY (2021)
Transplant Oncology: An Evolving Field in Cancer Care
Maen Abdelrahim et al.
CANCERS (2021)
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
Milind Javle et al.
Lancet Gastroenterology & Hepatology (2021)
Immunotherapy for cholangiocarcinoma: a 2021 update
Nikolaos Charalampakis et al.
IMMUNOTHERAPY (2021)
Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.
Keun Wook Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Recent Advances in Systemic Treatments for HER-2 Positive Advanced Gastric Cancer
Seda Kahraman et al.
ONCOTARGETS AND THERAPY (2021)
Cholangiocarcinoma
Paul J. Brindley et al.
NATURE REVIEWS DISEASE PRIMERS (2021)
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation The Phase 3 Randomized Clinical ClarIDHy Trial
Andrew X. Zhu et al.
JAMA ONCOLOGY (2021)
FIGHT-302: Phase III study of first-line (1L) pemigatinib (PEM) versus gemcitabine (GEM) plus cisplatin (CIS) for cholangiocarcinoma (CCA) with FGFR2 fusions or rearrangements.
Tanios S. Bekaii-Saab et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A meta-analysis of the efficacy of postoperative adjuvant radiotherapy versus no radiotherapy for extrahepatic cholangiocarcinoma and gallbladder carcinoma
Bixin Ren et al.
RADIATION ONCOLOGY (2020)
Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer
Chennianci Zhu et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2020)
FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements.
Lipika Goyal et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models
Phillip C. C. Liu et al.
PLOS ONE (2020)
Ivosidenib in IDH1-mutant, chemotherapy-refractory Croatia& cholangiocarcinoma (ClarlDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Ghassan K. Abou-Alfa et al.
LANCET ONCOLOGY (2020)
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Ghassan K. Abou-Alfa et al.
LANCET ONCOLOGY (2020)
Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
Charles Pottier et al.
CANCERS (2020)
Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial
Shalini Makawita et al.
FUTURE ONCOLOGY (2020)
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Jesus M. Banales et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
Latest evidence on immunotherapy for cholangiocarcinoma
Xurui Guo et al.
ONCOLOGY LETTERS (2020)
Systemic treatment of advanced or recurrent biliary tract cancer
Wei Zhang et al.
BIOSCIENCE TRENDS (2020)
Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma
Paola Bertuccio et al.
JOURNAL OF HEPATOLOGY (2019)
Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials
Maria Maddalena Simile et al.
MEDICINA-LITHUANIA (2019)
Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors
Shuyan Dai et al.
CELLS (2019)
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
Vincenzo Mazzaferro et al.
BRITISH JOURNAL OF CANCER (2019)
Biological Role and Therapeutic Potential of IDH Mutations in Cancer
Matthew S. Waitkus et al.
CANCER CELL (2018)
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Milind Javle et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype
Apurva Jain et al.
JCO PRECISION ONCOLOGY (2018)
The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
Teresa Helsten et al.
CLINICAL CANCER RESEARCH (2016)
IDH mutations in cancer and progress toward development of targeted therapeutics
L. Dang et al.
ANNALS OF ONCOLOGY (2016)
Increasing mortality in the United States from cholangiocarcinoma: an analysis of the National Center for Health Statistics Database
Kaelan J. Yao et al.
BMC GASTROENTEROLOGY (2016)
Antibody-drug conjugates-an emerging class of cancer treatment
Nikolaos Diamantis et al.
BRITISH JOURNAL OF CANCER (2016)
Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study
Grazia Palomba et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
Jesus M. Banales et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2016)
Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Enterologues Oncologues
Bertrand Brieau et al.
CANCER (2015)
The Global Burden of Cancer 2013 Global Burden of Disease Cancer Collaboration
Christina Fitzmaurice et al.
JAMA ONCOLOGY (2015)
Multiple molecular pathways in melanomagenesis: characterization of therapeutic targets
Giuseppe Palmieri et al.
FRONTIERS IN ONCOLOGY (2015)
IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition
Andrew Kernytsky et al.
BLOOD (2015)
Second-line chemotherapy in advanced biliary cancer: a systematic review
A. Lamarca et al.
ANNALS OF ONCOLOGY (2014)
Second-line systemic treatment for advanced cholangiocarcinoma
Jane Elizabeth Rogers et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Roles of liver fluke infection as risk factor for cholangiocarcinoma
Paiboon Sithithaworn et al.
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES (2014)
Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes
Daniela Sia et al.
GASTROENTEROLOGY (2013)
Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation
Fang Wang et al.
SCIENCE (2013)
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Chao Lu et al.
NATURE (2012)
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Sevin Turcan et al.
NATURE (2012)
The global epidemiology of clonorchiasis and its relation with cholangiocarcinoma
Men-Bao Qian et al.
Infectious Diseases of Poverty (2012)
Clinical diagnosis and staging of cholangiocarcinoma
Boris Blechacz et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2011)
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Maria E. Figueroa et al.
CANCER CELL (2010)
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.
Juan Valle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Fibroblast growth factor signalling: from development to cancer
Nicholas Turner et al.
NATURE REVIEWS CANCER (2010)
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Lenny Dang et al.
NATURE (2009)
Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome
Elaine R. Mardis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Cholangiocarcinoma complicating primary sclerosing cholangitis: A 24-year experience
G. Morris-Stiff et al.
DIGESTIVE SURGERY (2008)
Cellular signaling by fibroblast growth factor receptors
VP Eswarakumar et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2005)
Monoclonal antibody therapy of cancer
GP Adams et al.
NATURE BIOTECHNOLOGY (2005)
The role of chemotherapy in cholangiocarcinoma
S Thongprasert
ANNALS OF ONCOLOGY (2005)